Our Global Commitment to Vaccine Access
October 8th, 2021
By Stéphane Bancel, Chief Executive Officer
When the COVID-19 pandemic struck, Moderna was an R&D-focused company that had yet to commercialize a product. But we believed our messenger RNA (mRNA) technology could make a difference, and within a very short time, we were able to advance our technology from the realm of scientific possibility, to authorized product and commercial production at unprecedented speed and scale. I want to thank our employees, our partners and the participants in our clinical trials who have been the heroes of our fight to end this pandemic.
Read more
Questions & Answers with Huijuan Li
May 26, 2021
Moderna People Profile
As we celebrated Asian and Pacific Islander Heritage Month, we caught up with our colleague Huijuan Li, who is a senior sponsor of Moderna’s ASPIRE (Asian & Pacific Islander Resources and Engagement) employee resource group.
Huijuan talks about accepting failure, turning the impossible into the possible, and the important role we can play in fostering diversity, inclusion and collaboration.
Read more
Taking the next steps on our CSR journey
April 27, 2021
The pandemic has disrupted life as we know it. It has had a disproportionate impact on the most vulnerable and marginalized communities. It has led to an increase in mental health challenges due to joblessness and lockdowns, lost educational opportunities for many children and a tragic loss of life around the world.
Despite all that it has taken away, the pandemic has given us the opportunity to reflect on what is truly important, how we treat one another, and how we as Moderna create value for all of our stakeholders.
Read more
mRNA Vaccines: This is just the beginning
April 26, 2021
Today marks the start of World Immunization Week, a time to reflect on the importance of vaccines and immunization. The past year, in particular, has underscored its significance and brought us hope that vaccinations can help control the COVID-19 pandemic and other deadly diseases. Vaccines are second to only the availability of clean water in the impact to public health1.
Read more
Diseases Don’t Discriminate—Neither Should Clinical Research
April 15, 2021
By Melanie Ivarsson, PhD, MBA, Chief Development Officer
Yesterday we hosted Moderna’s annual Vaccines Day during which we announced two important clinical milestones in our prophylactic vaccines core modality: new positive interim Phase 1 data from our Respiratory Syncytial Virus (RSV) vaccine candidate and new 7-month interim Phase 2 data from our cytomegalovirus (CMV) vaccine candidate.
Read more
Moderna Ships 100 Millionth Dose of COVID-19 Vaccine to the U.S. Government
March 29, 2021
By Stéphane Bancel, Chief Executive Officer
We are proud to announce today that Moderna has shipped the 100 millionth dose of the Moderna COVID-19 Vaccine to the United States government. This is a most heartening milestone.
In a year that has been both historic and life-changing for almost everyone, so many of us have come together across business, government and civil society to make what is proving to be a profound impact. We knew from the very beginning that no one could do this alone. The Moderna team feels a deep sense of responsibility and pride in having been able to be part of the solution.
Read more
Rallying for Rare: Working Together to Help Patients in Need
February 28, 2021
By Ruchira Glaser, M.D., M.S., Senior Vice President, Therapeutic Area Head, Rare Disease, Autoimmune & Cardiovascular
Only by working together can we maximize our impact on patients. We know that great science is being done around the world, and we are committed to being a part of this broader ecosystem as our team works to deliver new mRNA medicines for patients with rare diseases. Also, only through strong partnerships with patients and advocates will we be able to deliver on the promise of mRNA for the rare disease community.
Read more
Questions & Answers with Alana Lewis
February 1, 2021
Moderna People Profile
As we prepared to celebrate Black History Month at Moderna, we caught up with our colleague Alana Lewis, who is the chair of Moderna’s Black and African-American Employee Resource Group.
Alana talks about her love of a good challenge, spending downtime on what truly matters, and the importance of reflection this time of year.
Read more
Moderna 2020 Shareholder Letter
January 4, 2020
By Stéphane Bancel, Chief Executive Officer
Dear fellow shareholders,
By nearly all measures, 2020 was a historic year in our lives. It was also a historic year for Moderna.
We started the year not knowing there was going to be a new virus, which would be declared a global pandemic—the first of its kind in 100 years since the Spanish flu. We ended the year with an Emergency Use Authorization from the U.S. Food and Drug Administration (FDA) and an Interim Order from Health Canada for use of our COVID-19 vaccine.
Read more
Moderna’s mRNA Vaccine Against COVID-19 Receives FDA Emergency Use Authorization
December 18, 2020
By Stéphane Bancel, Chief Executive Officer
Today, the U.S. Food and Drug Administration (FDA) has authorized the emergency use of the Moderna COVID-19 Vaccine. This marks a bright spot in a year defined by the biggest public health crisis of our lives, disruption, uncertainty and loss for many of us, and a significant milestone in our fight against the pandemic virus.
Read more
Questions & Answers with Anisa Gandhi
June 30, 2020
Moderna People Profile
We caught up with our colleague Anisa Gandhi, who works at Moderna’s Technology Center, to hear her perspective on how values and culture drive workplace behavior.
Anisa talks collaboration, leading by example and what it means to build a culture of quality.
Read more
Questions & Answers with Kathrin Jinivizian
April 17, 2020
Moderna People Profile
As we neared the end of Women’s History Month, we caught up with our colleague Kathrin Jinivizian online, keeping a safe social distance during the COVID-19 outbreak.
Kathrin talks about revolutionizing medicine, women in manufacturing, and reaching a broad range of people to do highly creative and heart-based work.
Read more
How Moderna is Building a Digital Biotech
March 2, 2020
At Moderna, building a digital biotech is a foundational component of who we are and is a key enabler of our mission to create a new class of mRNA medicines for patients. Incorporating digital into everything we do is mission-critical to us.
Read more
Moderna Manufacturing: Why Norwood?
March 2, 2020
We believe manufacturing plays a critical role in our value chain and ability to develop a new category of medicines.
Read more
Rare Isn’t Rare: Accelerating Progress in Rare Disease Treatment
February 28, 2020
By Kelly Lindert, M.D., Head of Metabolic Rare Diseases Clinical Development
Moderna’s mission is to deliver on the promise of mRNA science to create a new generation of transformative medicines for patients, including those with certain rare diseases.
Read more
